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Introduction
Cerebral ischemia and temporal lobe epilepsy carry a high risk of permanent brain damage mainly due to excitotoxic cell death. These both pathologies have therapeutic and economic considerations, because they affect almost 2% of the intellectual deficits. Cerebral ischemia is the third cause of mortality and the first cause of long term disability. Temporal lobe epilepsy (TLE), characterized by recurrent complex partial seizures (SRS) is one of the most prevalent forms of epilepsy and is frequently associated with pharmacoresistance. During an ischemia or an epilepsy, neurons at risk die as a result of a neurotoxic biochemical cascade initiated by reduced energy stores, membrane depolarisation, excessive neurotransmitter release, accumulation of free fatty acids and lysophospholipids, elevated intracellular calcium, increased oxygen free radicals and neuronal hyperexcitability [1] . The evolution of the major pathophysiological entities of tissue destruction in stroke and epilepsy follows a temporal profile going from minutes-hours to weeks, which corresponds to the acute mechanisms of excitotoxicity and the delayed mechanisms of apoptosis and inflammation leading to the neuronal damage. Since classical therapeutic strategies, that consist in blocking the death pathways were unsuccessful to pass from the bench to the bedside, it can be interesting to test an alternative approach that consists to increase the neuronal resistance by using the activation of potassium channels (K + channels) to prevent the neuronal hyperexcitability. K + channels are known to be involved in the endogenous regulation of the nervous cell excitability. Opening of K + channels may reduce the depolarization triggered by ischemia or epileptic seizure and consequently may reduce brain damage. At a presynaptic level, the K (20 min [2] . These K 2P channels (also called background K + channels) and their regulation by membrane-receptor-coupled second messengers, as well as pharmacological agents are therefore important in tuning neuronal resting membrane potential, action potential duration, membrane input resistance and, consequently regulating transmitter release [3] . The class of mammalian K 2P channel subunits now includes 15 members. One of them is the TREK-1 channel, which is the most extensively studied [4] [5] [6] . The specificity of its regulation is particularly interesting in relation with neuronal disease states. Mechano-gated and arachidonic acid-activated TWIK-related K + 1 (TREK-1), highly expressed in the brain [7] is a signal integrator responding to a wide range of physiological and pathological inputs. It can be activated by physical stimuli such as stretch, depolarization, intracellular acidosis and warm temperature. In relation with neuroprotection, TREK-1 is upmodulated by volatile anaesthetics, riluzole [8] (a well-known neuroprotective agent) [9] [10] [11] [12] and also with lysophospholipids and polyunsaturated fatty acids (PUFA) including arachidonic acid (AA), docosahexaenoic acid (DHA) and alpha-linolenic acid (ALA) [6, 13] .
PUFA and neuronal protection
Using in vivo models of ischemia, our laboratory has shown that PUFAs are able to induce a strong neuronal protection against the deleterious effects of cerebral [14, 15] and spinal [16] ischemia. In the model of global ischemia [14] , induced in rats by cauterization of vertebral arteries and transient (20 min) clamping of both carotids, an intravenous injection of ALA at a dose of 500 nmoles/kg 30 min up to 2 hours post-ischemia strongly reduces the neuronal loss of CA1 pyramidal cell layer induced by severe ischemia and blocks apoptosis revealed by TUNEL assay ( figure 1) . The transient (60 min) occlusion of middle cerebral artery (focal ischemia) induces in mice focal cortical and subcortical lesions and reproduces human clinical observations of a stroke. The quantitation of infarct volume at 24-hour postischemia shows that an injection of ALA, but not palmitic acid, a saturated fatty acid reduces the infarction volume with a therapeutic window from 30 min to 6 hours postischemia [15] . Interestingly, at one month after reperfusion, the best protection is obtained with a threeweek therapy of ALA (250 nmoles/kg) with a 70% survival rate ( figure 1) . Spinal ischemia is a devastating complication of thoracic and thoracoabdominal aortic surgery, which induces a severe and often definitive paraplegia. In the model of spinal ischemia [16] , rats are submitted to cross-clamping of the aortic arch and left subclavian artery for 15 min. The rats treated with 200 nmol/kg of ALA at the onset of reperfusion have a better neurologic function (figure 2). PUFA are also able to induce a brain tolerance [17] . Cerebral preconditioning is a powerful endogenous protective mechanism in which moderate ischemic or epileptic insult provide a neuroprotective adaptation of the brain against subsequent severe ischemic or epileptic insult, normally lethal for neurons [18] . Because ATP-sensitive potassium channels opening through adenosine A 1 receptor activation are a central early step in cerebral preconditioning, it is possible to mimic preconditioning pharmacologically with adenosine agonists and K ATP openers [19, 20] . Similarly, an intravenous injection of ALA at 500 nanomoles/kg induce a potent brain tolerance when it is administered as early as 3 days before severe ischemic or epileptic injury [21] (figure 2). Palmitic acid, which does not activate TREK-1 channels fails to protect the brain in both pathologies. The potent delayed neuroprotection induced by ischemic, epileptic or pharmacological preconditioning requires de novo synthesis of proteins including manganese superoxide dismutase, Bcl 2 and heat shock protein 70 in the time window of protection (1 to 3 days). ALA-induced preconditioning induces a strong HSP70 expression in the cerebral structures including the CA1 region of hippocampus, normally damaged by severe ischemia [17] (figure 2).
. ALA-induced neuroprotection in a model of spinal ischemia (40 min) and in brain tolerance. A) Neurologic score (Tarlov) after 24 hours of reperfusion. B) Ischemic tolerance induced by a ALA-pretreatment (500 nmol/kg 3 days before 6 min global ischemia). a: Representative photographs of hippocampal CA1 region

TREK-1 channel, lipids and neuronal protection
The TREK-1 channels have no specific blockers. In order to study the physiopathological role of TREK-1 in vivo, its gene has been disrupted by homologous recombination in the mouse. Using this knockout (KO) mouse model, recent studies indicate a central role for TREK-1 in general anaesthesia, pain perception, depression and neuroprotection [13, [22] [23] [24] . 
Conclusion
It has been well established that PUFA and particularly ALA and DHA administered in acute treatment are potent neuroprotectors against ischemia and epilepsy. In term of prevention, PUFA induce a strong ischemic and epileptic tolerance. of this K + channel in PUFA-neuroprotection. At the pharmacological level, future studies will be needed to identify high-affinity openers of the TREK-1 channel that might prove useful for the treatment of a range of neuronal disease states.
